Offerings
Uses
The Race
About Us
Resources
Create a CKB Account
Create a mastermind account

Clinical Diagnostics

Accelerate NGS variant interpretation with rapid search and insight into the full text of the genomic literature

Clinical Uses

Precision Therapeutics

Partner with us to gain a comprehensive view of the genetics of your disease of interest, from discovery to commercialization

Pharma Uses

Software Solutions

Explore our platforms for germline and somatic variant interpretation


Access article information on more than 26 million variants, as well as curated germline variant content.

Meet Mastermind

Our Cancer Knowledgebase is used to interpret cancer variants, connecting them to therapies and clinical trials


Meet CKB

Services

Partner with our team of experts to create Tailored Solutions for your unique needs

Clinical Diagnostic Services
Precision Therapeutics Services

Data

Gain access to an expansive, constantly updated database of curated genomic information

Learn More
Offerings
Software
Clinical Diagnostics Services
Precision Therapeutics Services
Data
Somatic Knowledgebase
Uses
The Race
About Us
Resources
schedule a discovery call
Create a mastermind account
Create a CKB Account
< News, Press, & Events

Press Release

Genomenon Announces Participation in BIO Partnering

FOR IMMEDIATE RELEASE‍

‍January 4, 2023 Ann Arbor, MI

Genomenon Announces Participation in BIO Partnering @JPM Week 2024

Executive Team to share the critical need of genomic information to support evidence-based decisions at every phase of drug programs

Genomenon, a genomic intelligence company, announced that it will be participating in BIO Partnering @JPM Week 2024, which takes place from January 8th to January 12th in San Francisco, California.

Details of the event are as follows:

Event: BIO Partnering @JPM Week
Date: January 8-12, 2024
Registration: https://www.bio.org/events/bio-partnering-jpm/registration

Genomenon executives will be available to conduct one-on-one meetings with registered pharmaceutical companies and investors. They are looking to raise awareness within cancer and genetic disease therapeutics regarding the hidden costs caused by a lack of access to comprehensive genomic information at every phase of a drug program. Schedule your meeting with the Genomenon’s leadership team by connecting with one of our team members through the BIO Partnering system.

About
Genomenon

Genomenon is a leading genomic intelligence company transforming patient care by uncovering the genomic drivers of genetic disease and cancer. By combining the power of AI built on the world’s premier genomic data set with genomic expertise, the company simplifies complex genetic data into actionable insights. Genomenon's integrated software, data, and services solutions empower clients with advanced patient diagnosis and precision medicine development.

About
BIO

BIO is the world’s largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the U.S. and in more than 30 other nations.

BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.

For more information, visit www.bio.org

‍

Read the Article
Offerings
SoftwarePrecision Therapeutics ServicesClinical Diagnostic ServicesData Access
Uses
Clinical UsesPharmaceutical Uses
The Race
About Us
Resources
Careers
News, Press & Events
Investors
Contact Us
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Citing MastermindTerms & ConditionsPrivacy PolicyCopyright © 2024 Genomenon, Inc. All rights reserved.

By using this website, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.

Accept